Recent Session:

International Perspectives on Value-Based Healthcare
Westchester Biotech Project Europe Launch

Launching Westchester biotech project europe

Launching Westchester biotech project europe

July 18, 2019

Recording PDF

Jason Helgerson, Founder
and Chief Solutions Officer
Helgerson Solutions Group

Vladimir Makarov
Pistoia Alliance

Philippe Salphati, PharmD
Managing Director, France-Switzerland & Partner
Tefen Consulting

Join your colleagues for a virtual, cross-Atlantic session to discuss emerging opportunities for international growth.

About Westchester Biotech Project Europe

Direct and agile collaboration without borders has become crucial to speeding up innovation and market access. The digital revolution has enabled landmark scientific and medical research progress unpredictable even a few years back. At the same time, expanding capital for early-stage start-ups is enabling the future success of these innovations.

To stimulate and strengthen connections across the Atlantic, we have recently signed a Memorandum of Understanding for Westchester Biotech Project Europe Read Press Release

This collaboration further engages the US-European scientific community, strengthening our connections with the international innovation scene. Mutual exchange programs are in the works, honoring the pivotal relationship between scientific disciplines and international regions.  

Seeing firsthand the fine work produced by the Westchester Biotech Project, this is an incredible partnership. Our relationship brings together industry experts and investors from both sides of the Atlantic Ocean to accelerate solutions addressing unmet life-threatening medical needs.
— Philippe Salphati, President and CEO, AYA Consulting

About our Speakers:

Among the developing relationships is with Sophia Antipolis, a 6,000-acre technology campus located southwest of Nice. Known as the “French Palo Alto,” Sophia Antipolis is regarded as an R&D and technology start-up hub, with as many as 2,500 companies, 4,500 researchers and 5,500 students from more than 64 countries located there. Sophia Antipolis specializes in computing, electronics, pharmacology, and biotechnology.

Westchester Biotech Project Europe aims to facilitate and accelerate the match between innovation and capital, speeding access to market. We aim to play an active and catalyst role in the development of the Sophia Antipolis community and beyond.

Who’s Involved? Westchester Biotech Project Europe works closely with public and private partners such as Foundation Sophia and Communauté d'agglomération de Sophia Antipolis, the organization representing the cities/towns engaged in the development of Sophia Antipolis. Other private and public partners will be joining soon. Engaging and involving organizations from across Europe will result in collaborative resources to the benefit of all parties involved.

Philippe Salphati, PharmD, Managing Director
France-Switzerland & Partner, Tefen Management Consulting
Formerly VP, Global Marketing, Sanofi Pasteur

Scott Fleming, Senior Vice President, BD Europe, Adherium
Karine Kleinhaus, MD, Principal, BioConnect
Antonio Molina-Pachon, Ph.D., CEO, GenCo Pharma
Michael Welling, Co-Founder and Chair, Westchester Biotech Project


Jason Helgerson, Founder and Chief Solutions Officer, Helgerson Solutions Group

Jason Helgerson is a social change agent. After more than 20 years of public service, most recently as New York’s Medicaid Director, he now is focused on helping companies, providers, payers and governments deliver value-based health care. 

Jason’s time is spent advising organisations and health systems across the US and further afield – with a focus on tackling the social determinants of health and bending cost curves.  His passions include creating effective value-based payment systems, facilitating successful cross-sector collaboration, and delivering transformative stakeholder engagement — all elements that underpin a successful value-based health and social care strategy.

Vladimir Makarov.jpg

Vladimir Makarov, Consultant, Pistoia Alliance

Dr. Makarov is a science consultant at the Pistoia Alliance and an Adjunct Professor of Bioinformatics and Biostatistics at California State University, Channel Islands. Previously Dr. Makarov was a start-up founder (latest sold in November 2015), and the Bioinformatics Lead at Monsanto. Dr. Makarov has worked for many of the major pharma and technology companies, including: Illumina, British Telecom, Amgen, Pfizer, Baxter, Celera Genomics, and with many small firms who have sought his expertise over the last twenty years. Dr. Makarov holds a Ph.D. in Computational Biology from Baylor College of Medicine in Houston, TX, and a MBA degree from Pepperdine University in Los Angeles.

Philippe Salphati.jpg

Philippe Salphati, PharmD, Managing Director, France-Switzerland & Partner, Tefen Management Consulting
Formerly VP, Global Marketing, Sanofi Pasteur

Dr. Salphati has over 25 years of global leadership experience in major life science companies, including Sanofi, which brought him to Rye for several years. He holds a Doctor of Pharmacy degree from the School of Pharmacy, Paris XI, and an MBA from the International University of America in San Francisco.


The Westchester Biotech Project Europe is a French-based NGO working to develop strong relationships throughout the continent, UK, and Israel. These connections will lead to fresh collaborations with US-based researchers and innovation centers.

To get involved, send a note and we'll connect you!

About Westchester Biotech Project

The Westchester Biotech Project brings together researchers, engineers, and data scientists from across therapeutics, diagnostics, and devices. Based in Westchester County, NY, this is a borderless initiative with opportunities for local, national, and international collaboration.

With recent lease signing for the North 60 project, Westchester County is positioned to grow as a magnet for the international biotech community. This is a perfect moment to strengthen international ties, and leverage lessons learned from emerging discovery-to-commercialization models. By building partnerships that endure, we can realize profound biomedical progress, and even cures.